01.15.13
John C. Reed, M.D., Ph.D., has been appointed head of Roche Pharma Research and Early Development (pRED) and member of the corporate executive committee, effective April 2, 2013. He will be based in Basel, reporting to Severin Schwan, chief executive officer of the Roche Group.
Prior to joining the company, he was chief executive officer at Sanford-Burnham Medical Research Institute in La Jolla, CA. He is a leading biomedical researcher with a focus on cancer, neuroprotection, autoimmunity, and other diseases. Dr. Reed has authored several hundred medical research publications and is among the world’s most highly cited scientists for his research contributions.
Mr. Schwan said, “We are delighted to welcome John Reed to Roche, who has led one of the world’s top laboratory-based medical research institutes. With his broad scientific and medical background he is ideally positioned to drive Roche’s strategy of translating a better understanding of disease mechanisms into promising therapeutics.”
Prior to joining the company, he was chief executive officer at Sanford-Burnham Medical Research Institute in La Jolla, CA. He is a leading biomedical researcher with a focus on cancer, neuroprotection, autoimmunity, and other diseases. Dr. Reed has authored several hundred medical research publications and is among the world’s most highly cited scientists for his research contributions.
Mr. Schwan said, “We are delighted to welcome John Reed to Roche, who has led one of the world’s top laboratory-based medical research institutes. With his broad scientific and medical background he is ideally positioned to drive Roche’s strategy of translating a better understanding of disease mechanisms into promising therapeutics.”